Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22071596,half-life,Peak plasma concentrations of afatinib were reached 3-4 h after administration and declined with a half-life of 30-40 h.,Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22071596/),h,30-40,22,DB00317,Gefitinib
,23064060,Cmax,"The Cmax of gefitinib in patients with a partial response(PR)was significantly lower than that of patients with stable disease(SD)(median Cmax: 278 vs 588 ng/mL, p<0.05 ).",The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064060/),[ng] / [ml],278,213,DB00317,Gefitinib
,23064060,Cmax,"The Cmax of gefitinib in patients with a partial response(PR)was significantly lower than that of patients with stable disease(SD)(median Cmax: 278 vs 588 ng/mL, p<0.05 ).",The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064060/),[ng] / [ml],588,214,DB00317,Gefitinib
,16507511,IC(50),Both gefitinib (IC(50) = 0.022 microM) and its desmethyl metabolite (0.036 microM) inhibited subcellular EGFR tyrosine kinase activity with a similar potency and selectivity.,"Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16507511/),μM,0.022,3850,DB00317,Gefitinib
,16507511,IC(50),Both gefitinib (IC(50) = 0.022 microM) and its desmethyl metabolite (0.036 microM) inhibited subcellular EGFR tyrosine kinase activity with a similar potency and selectivity.,"Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16507511/),μM,0.036,3851,DB00317,Gefitinib
,16507511,IC(50),"However, desmethyl-gefitinib (IC(50) = 0.76 microM) was 15 times less active than gefitinib (0.049 microM) against EGF-stimulated KB cell growth in a whole cell assay.","Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16507511/),μM,0.76,3852,DB00317,Gefitinib
,16507511,IC(50),"However, desmethyl-gefitinib (IC(50) = 0.76 microM) was 15 times less active than gefitinib (0.049 microM) against EGF-stimulated KB cell growth in a whole cell assay.","Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16507511/),μM,0.049,3853,DB00317,Gefitinib
,16507511,AUC,"Tumour concentrations of gefitinib (AUC = 300 microg h g(-1)) were much higher than those of desmethyl-gefitinib (44.3 microg h g(-1)), although plasma concentrations of gefitinib (48.4 microg h ml(-1)) and desmethyl-gefitinib (39.0 microg h ml(-1)) were quite similar at these dose levels.","Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16507511/),[h·μg] / [g],300,3854,DB00317,Gefitinib
,16507511,AUC,"Tumour concentrations of gefitinib (AUC = 300 microg h g(-1)) were much higher than those of desmethyl-gefitinib (44.3 microg h g(-1)), although plasma concentrations of gefitinib (48.4 microg h ml(-1)) and desmethyl-gefitinib (39.0 microg h ml(-1)) were quite similar at these dose levels.","Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16507511/),[h·μg] / [g],44.3,3855,DB00317,Gefitinib
,16507511,AUC,"Tumour concentrations of gefitinib (AUC = 300 microg h g(-1)) were much higher than those of desmethyl-gefitinib (44.3 microg h g(-1)), although plasma concentrations of gefitinib (48.4 microg h ml(-1)) and desmethyl-gefitinib (39.0 microg h ml(-1)) were quite similar at these dose levels.","Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16507511/),[h·μg] / [ml],48.4,3856,DB00317,Gefitinib
,16507511,AUC,"Tumour concentrations of gefitinib (AUC = 300 microg h g(-1)) were much higher than those of desmethyl-gefitinib (44.3 microg h g(-1)), although plasma concentrations of gefitinib (48.4 microg h ml(-1)) and desmethyl-gefitinib (39.0 microg h ml(-1)) were quite similar at these dose levels.","Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16507511/),[h·μg] / [ml],39.0,3857,DB00317,Gefitinib
,17317832,C(max),Mean (+/-SD) serum calcitriol C(max) at the MTD was 6.68 +/- 1.42 ng/mL.,A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17317832/),[ng] / [ml],6.68,5382,DB00317,Gefitinib
,25554506,area under the concentration-time curve from 0 to 24 hours (AUC0-24),"The median area under the concentration-time curve from 0 to 24 hours (AUC0-24) and trough plasma concentration (C0) of gefitinib was 10,086 ng · h/mL (range, 3247-24,726 ng · h/mL) and 334 ng/mL (range, 77.9-813 ng/mL), respectively.","Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25554506/),[h·ng] / [ml],"10,086",6588,DB00317,Gefitinib
,25554506,trough plasma concentration (C0),"The median area under the concentration-time curve from 0 to 24 hours (AUC0-24) and trough plasma concentration (C0) of gefitinib was 10,086 ng · h/mL (range, 3247-24,726 ng · h/mL) and 334 ng/mL (range, 77.9-813 ng/mL), respectively.","Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25554506/),[ng] / [ml],334,6589,DB00317,Gefitinib
,25554506,AUC0-24,"However, the AUC0-24 and C0 levels of gefitinib in the patients with diarrhea or hepatotoxicity were significantly greater than in those without (diarrhea: AUC0-24, 14,246 vs. 8918 ng · h/mL, P = .006; C0: 421 vs. 261 ng/mL, P = .002; hepatotoxicity: AUC0-24, 12,967 vs. 8473 ng · h/mL, P = .024; C0: 420 vs. 248 ng/mL, P = .002).","Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25554506/),[h·ng] / [ml],"14,246",6590,DB00317,Gefitinib
,25554506,AUC0-24,"However, the AUC0-24 and C0 levels of gefitinib in the patients with diarrhea or hepatotoxicity were significantly greater than in those without (diarrhea: AUC0-24, 14,246 vs. 8918 ng · h/mL, P = .006; C0: 421 vs. 261 ng/mL, P = .002; hepatotoxicity: AUC0-24, 12,967 vs. 8473 ng · h/mL, P = .024; C0: 420 vs. 248 ng/mL, P = .002).","Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25554506/),[h·ng] / [ml],8918,6591,DB00317,Gefitinib
,25554506,C0,"However, the AUC0-24 and C0 levels of gefitinib in the patients with diarrhea or hepatotoxicity were significantly greater than in those without (diarrhea: AUC0-24, 14,246 vs. 8918 ng · h/mL, P = .006; C0: 421 vs. 261 ng/mL, P = .002; hepatotoxicity: AUC0-24, 12,967 vs. 8473 ng · h/mL, P = .024; C0: 420 vs. 248 ng/mL, P = .002).","Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25554506/),[ng] / [ml],421,6592,DB00317,Gefitinib
,25554506,C0,"However, the AUC0-24 and C0 levels of gefitinib in the patients with diarrhea or hepatotoxicity were significantly greater than in those without (diarrhea: AUC0-24, 14,246 vs. 8918 ng · h/mL, P = .006; C0: 421 vs. 261 ng/mL, P = .002; hepatotoxicity: AUC0-24, 12,967 vs. 8473 ng · h/mL, P = .024; C0: 420 vs. 248 ng/mL, P = .002).","Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25554506/),[ng] / [ml],261,6593,DB00317,Gefitinib
,25554506,AUC0-24,"However, the AUC0-24 and C0 levels of gefitinib in the patients with diarrhea or hepatotoxicity were significantly greater than in those without (diarrhea: AUC0-24, 14,246 vs. 8918 ng · h/mL, P = .006; C0: 421 vs. 261 ng/mL, P = .002; hepatotoxicity: AUC0-24, 12,967 vs. 8473 ng · h/mL, P = .024; C0: 420 vs. 248 ng/mL, P = .002).","Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25554506/),[h·ng] / [ml],"12,967",6594,DB00317,Gefitinib
,25554506,AUC0-24,"However, the AUC0-24 and C0 levels of gefitinib in the patients with diarrhea or hepatotoxicity were significantly greater than in those without (diarrhea: AUC0-24, 14,246 vs. 8918 ng · h/mL, P = .006; C0: 421 vs. 261 ng/mL, P = .002; hepatotoxicity: AUC0-24, 12,967 vs. 8473 ng · h/mL, P = .024; C0: 420 vs. 248 ng/mL, P = .002).","Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25554506/),[h·ng] / [ml],8473,6595,DB00317,Gefitinib
,25554506,C0,"However, the AUC0-24 and C0 levels of gefitinib in the patients with diarrhea or hepatotoxicity were significantly greater than in those without (diarrhea: AUC0-24, 14,246 vs. 8918 ng · h/mL, P = .006; C0: 421 vs. 261 ng/mL, P = .002; hepatotoxicity: AUC0-24, 12,967 vs. 8473 ng · h/mL, P = .024; C0: 420 vs. 248 ng/mL, P = .002).","Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25554506/),[ng] / [ml],420,6596,DB00317,Gefitinib
,25554506,C0,"However, the AUC0-24 and C0 levels of gefitinib in the patients with diarrhea or hepatotoxicity were significantly greater than in those without (diarrhea: AUC0-24, 14,246 vs. 8918 ng · h/mL, P = .006; C0: 421 vs. 261 ng/mL, P = .002; hepatotoxicity: AUC0-24, 12,967 vs. 8473 ng · h/mL, P = .024; C0: 420 vs. 248 ng/mL, P = .002).","Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25554506/),[ng] / [ml],248,6597,DB00317,Gefitinib
,27422720,disease control rate,A best response of stable disease was achieved by 2/11 patients in Part A and 4/6 patients in Part B (disease control rate: 35 %).,"A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27422720/),%,35,8740,DB00317,Gefitinib
,19497691,gastric emptying T90,"The rapid clearance cohorts were shown to have a faster mean gastric emptying T90 (37 min vs 74 min) and shorter small intestinal transit time (156 min vs 204 min), resulting in an earlier colonic arrival time (181 min vs 244 min).",Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19497691/),min,37,9913,DB00317,Gefitinib
,19497691,gastric emptying T90,"The rapid clearance cohorts were shown to have a faster mean gastric emptying T90 (37 min vs 74 min) and shorter small intestinal transit time (156 min vs 204 min), resulting in an earlier colonic arrival time (181 min vs 244 min).",Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19497691/),min,74,9914,DB00317,Gefitinib
,19497691,small intestinal transit time,"The rapid clearance cohorts were shown to have a faster mean gastric emptying T90 (37 min vs 74 min) and shorter small intestinal transit time (156 min vs 204 min), resulting in an earlier colonic arrival time (181 min vs 244 min).",Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19497691/),min,156,9915,DB00317,Gefitinib
,19497691,small intestinal transit time,"The rapid clearance cohorts were shown to have a faster mean gastric emptying T90 (37 min vs 74 min) and shorter small intestinal transit time (156 min vs 204 min), resulting in an earlier colonic arrival time (181 min vs 244 min).",Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19497691/),min,204,9916,DB00317,Gefitinib
,19497691,colonic arrival time,"The rapid clearance cohorts were shown to have a faster mean gastric emptying T90 (37 min vs 74 min) and shorter small intestinal transit time (156 min vs 204 min), resulting in an earlier colonic arrival time (181 min vs 244 min).",Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19497691/),min,181,9917,DB00317,Gefitinib
,19497691,colonic arrival time,"The rapid clearance cohorts were shown to have a faster mean gastric emptying T90 (37 min vs 74 min) and shorter small intestinal transit time (156 min vs 204 min), resulting in an earlier colonic arrival time (181 min vs 244 min).",Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19497691/),min,244,9918,DB00317,Gefitinib
,19497691,plasma C(max),Mean plasma C(max) was lower (99.2 ng/mL vs 116 ng/mL) and AUC almost half in the rapid clearance group (2162+/-81 ngh/mL vs 4996+/-64 ngh/mL).,Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19497691/),[ng] / [ml],99.2,9919,DB00317,Gefitinib
,19497691,plasma C(max),Mean plasma C(max) was lower (99.2 ng/mL vs 116 ng/mL) and AUC almost half in the rapid clearance group (2162+/-81 ngh/mL vs 4996+/-64 ngh/mL).,Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19497691/),[ng] / [ml],116,9920,DB00317,Gefitinib
,19497691,AUC,Mean plasma C(max) was lower (99.2 ng/mL vs 116 ng/mL) and AUC almost half in the rapid clearance group (2162+/-81 ngh/mL vs 4996+/-64 ngh/mL).,Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19497691/),[ngh] / [ml],2162,9921,DB00317,Gefitinib
,19497691,AUC,Mean plasma C(max) was lower (99.2 ng/mL vs 116 ng/mL) and AUC almost half in the rapid clearance group (2162+/-81 ngh/mL vs 4996+/-64 ngh/mL).,Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19497691/),[ngh] / [ml],4996,9922,DB00317,Gefitinib
,24413624,AUC₀₋₂₄,"The median AUC₀₋₂₄ and C(0h) of gefitinib in patients with diarrhea (n = 8) were higher than those without diarrhea (n = 10) (15,043 versus 8918 ng·h·mL⁻¹, respectively, P = 0.0164 and 542 versus 261 ng/mL, respectively, P = 0.0263).",A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24413624/),h·ml⁻¹·ng,"15,043",11828,DB00317,Gefitinib
,24413624,AUC₀₋₂₄,"The median AUC₀₋₂₄ and C(0h) of gefitinib in patients with diarrhea (n = 8) were higher than those without diarrhea (n = 10) (15,043 versus 8918 ng·h·mL⁻¹, respectively, P = 0.0164 and 542 versus 261 ng/mL, respectively, P = 0.0263).",A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24413624/),h·ml⁻¹·ng,8918,11829,DB00317,Gefitinib
,24413624,C(0h),"The median AUC₀₋₂₄ and C(0h) of gefitinib in patients with diarrhea (n = 8) were higher than those without diarrhea (n = 10) (15,043 versus 8918 ng·h·mL⁻¹, respectively, P = 0.0164 and 542 versus 261 ng/mL, respectively, P = 0.0263).",A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24413624/),[ng] / [ml],542,11830,DB00317,Gefitinib
,24413624,C(0h),"The median AUC₀₋₂₄ and C(0h) of gefitinib in patients with diarrhea (n = 8) were higher than those without diarrhea (n = 10) (15,043 versus 8918 ng·h·mL⁻¹, respectively, P = 0.0164 and 542 versus 261 ng/mL, respectively, P = 0.0263).",A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24413624/),[ng] / [ml],261,11831,DB00317,Gefitinib
,24413624,C(0h),"The area under the receiver operator curve was 0.813, giving the best sensitivity (75%) and specificity (90%) at a C(0h) threshold of 398 ng/mL.",A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24413624/),[ng] / [ml],398,11832,DB00317,Gefitinib
,15764411,Binding,Binding to plasma proteins was high (86-94%) across the range of species examined and was 91% in human plasma.,"Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15764411/),%,86-94,13395,DB00317,Gefitinib
,15764411,Binding,Binding to plasma proteins was high (86-94%) across the range of species examined and was 91% in human plasma.,"Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15764411/),%,91,13396,DB00317,Gefitinib
,33196042,mPFS,"The mPFS of osimertinib before dose escalation was 11.4 ± 8.9 (6.6-30.7) months for arm A, 8.7 ± 1.8 (6.3-11.2) for arm B, and 14.5 ± 7.8 (6.7-22.3) for arm C.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),month,11.4,26195,DB00317,Gefitinib
,33196042,mPFS,"The mPFS of osimertinib before dose escalation was 11.4 ± 8.9 (6.6-30.7) months for arm A, 8.7 ± 1.8 (6.3-11.2) for arm B, and 14.5 ± 7.8 (6.7-22.3) for arm C.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),,8.7,26196,DB00317,Gefitinib
,33196042,mPFS,"The mPFS of osimertinib before dose escalation was 11.4 ± 8.9 (6.6-30.7) months for arm A, 8.7 ± 1.8 (6.3-11.2) for arm B, and 14.5 ± 7.8 (6.7-22.3) for arm C.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),,14.5,26197,DB00317,Gefitinib
,33196042,Intracranial response rate,Intracranial response rate to dose escalation was 54% (6 of 11) with 2 of 11 having intracranial stability.,Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),%,54,26198,DB00317,Gefitinib
,33196042,iPFS,"Median iPFS was 4.3 ± 7.4 (0.7-25.5) months; 3.8 ± 6.4 (1.8-18.9), 5.6 ± 9.7 (0.7-25.5), and 7.0 ± 2.7 (4.3-9.6) for arms A/B/C, respectively.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),month,4.3,26199,DB00317,Gefitinib
,33196042,iPFS,"Median iPFS was 4.3 ± 7.4 (0.7-25.5) months; 3.8 ± 6.4 (1.8-18.9), 5.6 ± 9.7 (0.7-25.5), and 7.0 ± 2.7 (4.3-9.6) for arms A/B/C, respectively.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),,3.8,26200,DB00317,Gefitinib
,33196042,iPFS,"Median iPFS was 4.3 ± 7.4 (0.7-25.5) months; 3.8 ± 6.4 (1.8-18.9), 5.6 ± 9.7 (0.7-25.5), and 7.0 ± 2.7 (4.3-9.6) for arms A/B/C, respectively.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),,5.6,26201,DB00317,Gefitinib
,33196042,iPFS,"Median iPFS was 4.3 ± 7.4 (0.7-25.5) months; 3.8 ± 6.4 (1.8-18.9), 5.6 ± 9.7 (0.7-25.5), and 7.0 ± 2.7 (4.3-9.6) for arms A/B/C, respectively.",Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196042/),,7.0,26202,DB00317,Gefitinib
,12796031,terminal half-life,Mean terminal half-life following multiple dosing was 50.1 h (range 27.8-79.7 h).,"Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12796031/),h,50.1,26540,DB00317,Gefitinib
,22753756,drug-loading efficiency (DLE),"The L-GEF formulation composed of hydrogenated soy phosphatidylcholine (HSPC)/cholesterol (Chol)/monomethoxy polyethylene glycol 2000-distearoyl phosphatidyl-ethanolamine (mPEG-DSPE) encapsulating 0.3 M (NH4)2SO4 and 0.1 M HPβCD (L-GEF-HSPC), had a drug-loading efficiency (DLE) of 85.5%.",Novel liposomal gefitinib (L-GEF) formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753756/),%,85.5,29895,DB00317,Gefitinib
,22753756,area under the plasma concentration time curve (AUC),Pharmacokinetic study in mice after i.v. bolus administration of L-GEF-HSPC showed that the area under the plasma concentration time curve (AUC) for gefitinib was 32.41 μg·h /ml and six times that of free gefitinib.,Novel liposomal gefitinib (L-GEF) formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753756/),[h·μg] / [ml],32.41,29896,DB00317,Gefitinib
,22753756,elimination half life (t(1/2β)),"The elimination half life (t(1/2β)) of L-GEF-HSPC was 7.29 h, while that of free gefitinib was 2.26 h.",Novel liposomal gefitinib (L-GEF) formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753756/),h,7.29,29897,DB00317,Gefitinib
,22753756,elimination half life (t(1/2β)),"The elimination half life (t(1/2β)) of L-GEF-HSPC was 7.29 h, while that of free gefitinib was 2.26 h.",Novel liposomal gefitinib (L-GEF) formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753756/),h,2.26,29898,DB00317,Gefitinib
,32436059,trough level,"The mean trough gefitinib level and AUC value for 24-h gefitinib concentration were significantly lower in the CA/AA group compared to the CC group (mean trough level: 333.2 vs. 454.5 ng/mL, respectively, P = 0.021; AUC: 9949.9 vs. 13,085.4 ng・h/mL, respectively, P = 0.034).",ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436059/),[ng] / [ml],333.2,30094,DB00317,Gefitinib
,32436059,trough level,"The mean trough gefitinib level and AUC value for 24-h gefitinib concentration were significantly lower in the CA/AA group compared to the CC group (mean trough level: 333.2 vs. 454.5 ng/mL, respectively, P = 0.021; AUC: 9949.9 vs. 13,085.4 ng・h/mL, respectively, P = 0.034).",ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436059/),[ng] / [ml],454.5,30095,DB00317,Gefitinib
,32436059,AUC,"The mean trough gefitinib level and AUC value for 24-h gefitinib concentration were significantly lower in the CA/AA group compared to the CC group (mean trough level: 333.2 vs. 454.5 ng/mL, respectively, P = 0.021; AUC: 9949.9 vs. 13,085.4 ng・h/mL, respectively, P = 0.034).",ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436059/),[ng・h] / [ml],9949.9,30096,DB00317,Gefitinib
,32436059,AUC,"The mean trough gefitinib level and AUC value for 24-h gefitinib concentration were significantly lower in the CA/AA group compared to the CC group (mean trough level: 333.2 vs. 454.5 ng/mL, respectively, P = 0.021; AUC: 9949.9 vs. 13,085.4 ng・h/mL, respectively, P = 0.034).",ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436059/),[ng・h] / [ml],"13,085.4",30097,DB00317,Gefitinib
,32436059,trough gefitinib level,"Among patients taking PPIs, the mean trough gefitinib level was significantly lower in the CA/AA group than the CC group (220.1 vs. 340.5 ng/mL, respectively, P = 0.033).",ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436059/),[ng] / [ml],220.1,30098,DB00317,Gefitinib
,32436059,trough gefitinib level,"Among patients taking PPIs, the mean trough gefitinib level was significantly lower in the CA/AA group than the CC group (220.1 vs. 340.5 ng/mL, respectively, P = 0.033).",ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436059/),[ng] / [ml],340.5,30099,DB00317,Gefitinib
,15156965,elimination half-life,Its elimination half-life is 14-48 hours.,Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156965/),h,14-48,40016,DB00317,Gefitinib
,15156965,response rate,Clinical trials have shown an average response rate of 93% when gefitinib is used as a second- or third-line agent.,Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15156965/),%,93,40017,DB00317,Gefitinib
,15764410,plasma half-life,"Following intravenous dosing (5 mg kg(-1), gefitinib plasma half-life was 3-6h in rats and dogs, although studies using a more sensitive HPLC-MS assay produced longer estimates of half-life (7-14h).","Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15764410/),h,3-6,42900,DB00317,Gefitinib
,15764410,half-life,"Following intravenous dosing (5 mg kg(-1), gefitinib plasma half-life was 3-6h in rats and dogs, although studies using a more sensitive HPLC-MS assay produced longer estimates of half-life (7-14h).","Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15764410/),h,7-14,42901,DB00317,Gefitinib
,15764410,plasma clearance,"In these studies, plasma clearance was high (male rat: 25 ml min(-1) kg(-1); female rat: 16 ml min(-1) kg(-1); male dog: 16 ml min(-1) kg(-1)), as was the volume of distribution (8.0-10.41 kg(-1) in rat; 6.31 kg(-1) in dog), and exposure in female rats was double that in males.","Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15764410/),[ml] / [kg·min],25,42902,DB00317,Gefitinib
,15764410,plasma clearance,"In these studies, plasma clearance was high (male rat: 25 ml min(-1) kg(-1); female rat: 16 ml min(-1) kg(-1); male dog: 16 ml min(-1) kg(-1)), as was the volume of distribution (8.0-10.41 kg(-1) in rat; 6.31 kg(-1) in dog), and exposure in female rats was double that in males.","Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15764410/),[ml] / [kg·min],16,42903,DB00317,Gefitinib
,15764410,volume of distribution,"In these studies, plasma clearance was high (male rat: 25 ml min(-1) kg(-1); female rat: 16 ml min(-1) kg(-1); male dog: 16 ml min(-1) kg(-1)), as was the volume of distribution (8.0-10.41 kg(-1) in rat; 6.31 kg(-1) in dog), and exposure in female rats was double that in males.","Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15764410/),1/[kg],8.0-10.41,42904,DB00317,Gefitinib
,15764410,volume of distribution,"In these studies, plasma clearance was high (male rat: 25 ml min(-1) kg(-1); female rat: 16 ml min(-1) kg(-1); male dog: 16 ml min(-1) kg(-1)), as was the volume of distribution (8.0-10.41 kg(-1) in rat; 6.31 kg(-1) in dog), and exposure in female rats was double that in males.","Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15764410/),1/[kg],6.31,42905,DB00317,Gefitinib
>,17482782,t(1/2),To investigate whether differences in plasma pharmacokinetic profiles of gefitinib between healthy subjects having normal (N; t(1/2)>20h) and altered (A; t(1/2)<20h) pharmacokinetic (PK) profiles might be explained by inter-individual variability in gastric emptying and/or precipitation/dissolution of gefitinib in the proximal small intestine.,Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17482782/),h,20,48032,DB00317,Gefitinib
<,17482782,t(1/2),To investigate whether differences in plasma pharmacokinetic profiles of gefitinib between healthy subjects having normal (N; t(1/2)>20h) and altered (A; t(1/2)<20h) pharmacokinetic (PK) profiles might be explained by inter-individual variability in gastric emptying and/or precipitation/dissolution of gefitinib in the proximal small intestine.,Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17482782/),h,20,48033,DB00317,Gefitinib
,21553932,Absolute bioavailability,Absolute bioavailability of gefitinib and erlotinib is about 60%.,Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21553932/),%,60,50892,DB00317,Gefitinib
,33012782,objective response rate,"In Arms 1 + 1a, objective response rate was 63.3% (95% CI: 43.9-80.1), median progression-free survival (PFS) was 10.1 months (95% CI: 5.5-15.2) and median response duration was 9.2 months (95% CI: 3.7-14.0).",A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012782/),%,63.3,55801,DB00317,Gefitinib
,33012782,progression-free survival (PFS),"In Arms 1 + 1a, objective response rate was 63.3% (95% CI: 43.9-80.1), median progression-free survival (PFS) was 10.1 months (95% CI: 5.5-15.2) and median response duration was 9.2 months (95% CI: 3.7-14.0).",A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012782/),month,10.1,55802,DB00317,Gefitinib
,33012782,response duration,"In Arms 1 + 1a, objective response rate was 63.3% (95% CI: 43.9-80.1), median progression-free survival (PFS) was 10.1 months (95% CI: 5.5-15.2) and median response duration was 9.2 months (95% CI: 3.7-14.0).",A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012782/),month,9.2,55803,DB00317,Gefitinib
,17312388,"C(ss,min)/C(1,min)","Gefitinib accumulation during 28 days of treatment (C(ss,min)/C(1,min)) was higher in patients heterozygous at the ABCG2 421C>A locus than those with a wild-type genotype (median, 5.07 vs. 3.60, p = 0.004).",Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312388/),,5.07,56187,DB00317,Gefitinib
,17312388,"C(ss,min)/C(1,min)","Gefitinib accumulation during 28 days of treatment (C(ss,min)/C(1,min)) was higher in patients heterozygous at the ABCG2 421C>A locus than those with a wild-type genotype (median, 5.07 vs. 3.60, p = 0.004).",Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312388/),,3.60,56188,DB00317,Gefitinib
,17148773,Midazola,"Midazolam clearance (mean = 40 L/h, range = 10-111) was highly correlated with that of total and unbound gefitinib (R2 = .60 and R2 = .68, respectively) and with steady-state plasma trough concentrations of gefitinib (R2 = .58 and R2 = .60, respectively), and it accounted for approximately 40% of interindividual variability in gefitinib clearance in the pharmacokinetic model.",CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17148773/),[l] / [h],40,58446,DB00317,Gefitinib
above,17148773,steady-state plasma trough concentrations,"At a dose of 250 mg gefitinib, 11 of 13 patients achieved steady-state plasma trough concentrations above the IC50 for inhibition of mutant EGFR in vitro (0.015 microM), but only one achieved a steady-state plasma trough concentration above the IC50 for inhibition of wild-type EGFR (0.1 microM).",CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17148773/),μM,0.015,58447,DB00317,Gefitinib
,17148773,steady-state plasma trough concentration,"At a dose of 250 mg gefitinib, 11 of 13 patients achieved steady-state plasma trough concentrations above the IC50 for inhibition of mutant EGFR in vitro (0.015 microM), but only one achieved a steady-state plasma trough concentration above the IC50 for inhibition of wild-type EGFR (0.1 microM).",CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17148773/),μM,0.1,58448,DB00317,Gefitinib
,17148773,IC50,"At a dose of 250 mg gefitinib, 11 of 13 patients achieved steady-state plasma trough concentrations above the IC50 for inhibition of mutant EGFR in vitro (0.015 microM), but only one achieved a steady-state plasma trough concentration above the IC50 for inhibition of wild-type EGFR (0.1 microM).",CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17148773/),μM,0.1,58449,DB00317,Gefitinib
,24011632,RE,"The result showed that RE of gefitinib at the concentrations of 1 μM and 10 μM was 4.12 and 4.05, respectively, but significantly decreased to 1 and 1.35 after adding a P-glycoprotein (P-gp) inhibitor, cyclosporine A.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,4.12,58993,DB00317,Gefitinib
,24011632,RE,"The result showed that RE of gefitinib at the concentrations of 1 μM and 10 μM was 4.12 and 4.05, respectively, but significantly decreased to 1 and 1.35 after adding a P-glycoprotein (P-gp) inhibitor, cyclosporine A.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,4.05,58994,DB00317,Gefitinib
,24011632,RE,"The result showed that RE of gefitinib at the concentrations of 1 μM and 10 μM was 4.12 and 4.05, respectively, but significantly decreased to 1 and 1.35 after adding a P-glycoprotein (P-gp) inhibitor, cyclosporine A.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,1,58995,DB00317,Gefitinib
,24011632,RE,"The result showed that RE of gefitinib at the concentrations of 1 μM and 10 μM was 4.12 and 4.05, respectively, but significantly decreased to 1 and 1.35 after adding a P-glycoprotein (P-gp) inhibitor, cyclosporine A.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,1.35,58996,DB00317,Gefitinib
,24011632,AUC(,"In BM model, AUC(totalbrain)/AUC(totalblood) in 50 mg/kg and 200 mg/kg groups were 0.4 and 0.7, respectively, while AUC(CSF)/AUC(freeblood) were 0.21 and 0.18, respectively.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,0.4,58997,DB00317,Gefitinib
,24011632,AUC(,"In BM model, AUC(totalbrain)/AUC(totalblood) in 50 mg/kg and 200 mg/kg groups were 0.4 and 0.7, respectively, while AUC(CSF)/AUC(freeblood) were 0.21 and 0.18, respectively.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,0.7,58998,DB00317,Gefitinib
,24011632,AUC(CSF)/AUC,"In BM model, AUC(totalbrain)/AUC(totalblood) in 50 mg/kg and 200 mg/kg groups were 0.4 and 0.7, respectively, while AUC(CSF)/AUC(freeblood) were 0.21 and 0.18, respectively.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,0.21,58999,DB00317,Gefitinib
,24011632,AUC(CSF)/AUC,"In BM model, AUC(totalbrain)/AUC(totalblood) in 50 mg/kg and 200 mg/kg groups were 0.4 and 0.7, respectively, while AUC(CSF)/AUC(freeblood) were 0.21 and 0.18, respectively.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,0.18,59000,DB00317,Gefitinib
,27154635,AUC0-24,"The median AUC0-24 of O-desmethyl gefitinib in CYP2D6 IMs was 1460 ng h/mL, whereas that in homozygous EMs was 12,523 ng h/mL (P = 0.021 in univariate analysis).","Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154635/),[h·ng] / [ml],1460,63416,DB00317,Gefitinib
,27154635,AUC0-24,"The median AUC0-24 of O-desmethyl gefitinib in CYP2D6 IMs was 1460 ng h/mL, whereas that in homozygous EMs was 12,523 ng h/mL (P = 0.021 in univariate analysis).","Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154635/),[h·ng] / [ml],"12,523",63417,DB00317,Gefitinib
,23334261,response rate,"The response rate was 50 % (10 of 20 patients), and the median progression-free survival (PFS) and overall survival times were 10.5 and 21.2 months, respectively.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),%,50,67587,DB00317,Gefitinib
,23334261,progression-free survival (PFS),"The response rate was 50 % (10 of 20 patients), and the median progression-free survival (PFS) and overall survival times were 10.5 and 21.2 months, respectively.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),month,10.5,67588,DB00317,Gefitinib
,23334261,overall survival times,"The response rate was 50 % (10 of 20 patients), and the median progression-free survival (PFS) and overall survival times were 10.5 and 21.2 months, respectively.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),month,21.2,67589,DB00317,Gefitinib
,23334261,PFS,"In EGFR mutation-positive patients (n = 9), seven patients achieved an objective response and the median PFS was 12.4 months, whereas none with wild-type EGFR (n = 6) responded.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),month,12.4,67590,DB00317,Gefitinib
≥,32402096,C0,"Patients having a gefitinib C0 of at least ≥200 ng/mL had significantly longer PFS than patients having a C0 of <200 ng/mL (median [95% confidence interval (CI)] PFS: 11.0 [8.2-13.7] and 5.3 [0.0-12.0] months, respectively, P = .042).",Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32402096/),[ng] / [ml],200,74419,DB00317,Gefitinib
<,32402096,C0,"Patients having a gefitinib C0 of at least ≥200 ng/mL had significantly longer PFS than patients having a C0 of <200 ng/mL (median [95% confidence interval (CI)] PFS: 11.0 [8.2-13.7] and 5.3 [0.0-12.0] months, respectively, P = .042).",Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32402096/),[ng] / [ml],200,74420,DB00317,Gefitinib
≥,32402096,C0,"There were no significant differences in PFS between patients with STAT3 rs4796793C/C and G alleles; however, patients with STAT3 rs4796793C/C having a gefitinib C0 of ≥ 200 ng/mL had significantly longer progression-free survival (PFS) and overall survival (OS) than those with a C0 of <200 ng/mL (median [95% CI] PFS: 11.4 [4.1-18.6] and 3.0 [0.0-7.0] months, respectively, P = .008; median [95% CI] OS: 20.6 [7.4-33.7] and 12.6 [10.1-15.1] months, respectively, P = .042).",Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32402096/),[ng] / [ml],200,74421,DB00317,Gefitinib
<,32402096,C0,"There were no significant differences in PFS between patients with STAT3 rs4796793C/C and G alleles; however, patients with STAT3 rs4796793C/C having a gefitinib C0 of ≥ 200 ng/mL had significantly longer progression-free survival (PFS) and overall survival (OS) than those with a C0 of <200 ng/mL (median [95% CI] PFS: 11.4 [4.1-18.6] and 3.0 [0.0-7.0] months, respectively, P = .008; median [95% CI] OS: 20.6 [7.4-33.7] and 12.6 [10.1-15.1] months, respectively, P = .042).",Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32402096/),[ng] / [ml],200,74422,DB00317,Gefitinib
,29335861,elimination half-life,Gefitinib was rapidly absorbed and showed a monoexponential decline with an elimination half-life of 3.7-4.1 h.,Alterations of Gefitinib Pharmacokinetics by Co-administration of Herbal Medications in Rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29335861/),h,3.7-4.1,74435,DB00317,Gefitinib
,26525154,flow rate,The three drugs were separated by high-performance liquid chromatography using a C18 column and an isocratic mobile phase running at a flow rate of 0.2 mL/min for 5 min.,"Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26525154/),[ml] / [min],0.2,78501,DB00317,Gefitinib
,29532998,50% inhibitory concentration (IC50 ),"It potently suppresses EGFRL858R/T790M with an 50% inhibitory concentration (IC50 ) value of 2.0 ± 0.3 nmol/L, but is approximately 92-folds less potent against EGFRWT kinase.","YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M -mutant resistance in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29532998/),[nM] / [l],2.0,80175,DB00317,Gefitinib
,29532998,oral bioavailability,It also exhibits acceptable pharmacokinetics (PK) parameters with an oral bioavailability value of 25.0% after oral administration in rats and exhibits promising antitumor efficacy in a gefitinib-resistant human H1975 xenografted model after oral administration of 30 mg/kg/day.,"YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M -mutant resistance in vitro and in vivo. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29532998/),%,25.0,80176,DB00317,Gefitinib
,16533791,IC50,The IC50 of YM-359445 for VEGFR2 tyrosine kinase was 0.0085 micromol/L.,"YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16533791/),[μM] / [l],0.0085,88615,DB00317,Gefitinib
,20458561,survival time (MST),Median survival time (MST) was 9.97 months (95%CI 2.79-17.14 months).,The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20458561/),month,9.97,88793,DB00317,Gefitinib
,20458561,trough gefitinib plasma concentration (Cminss,The geometric mean trough gefitinib plasma concentration (Cminss was 266 ng/ml (range 94-538 ng/ml).,The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20458561/),[ng] / [ml],266,88794,DB00317,Gefitinib
≥,20458561,Cminss,"In the multivariate analysis, only skin rash was associated with gefitinib-induced disease control (P=0.017); Adenocarcinoma, skin rash, and 'high' Cminss (Cminss≥200 ng/ml) were independently associated with overall survival (P=0.004, 0.028,0.007, respectively).",The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20458561/),[ng] / [ml],200,88795,DB00317,Gefitinib
,16719544,AUCinfinity,"Gefitinib geometric mean AUCinfinity and peak plasma drug concentration were higher in poor CYP2D6 metabolisers compared with extensive metabolisers (AUCinfinity 3060 vs 1430 ng . h/mL, p < 0.05, ANOVA), although the range of values was wide with considerable overlap between the groups.",Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719544/),[h·ng] / [ml],3060,89609,DB00317,Gefitinib
,16719544,AUCinfinity,"Gefitinib geometric mean AUCinfinity and peak plasma drug concentration were higher in poor CYP2D6 metabolisers compared with extensive metabolisers (AUCinfinity 3060 vs 1430 ng . h/mL, p < 0.05, ANOVA), although the range of values was wide with considerable overlap between the groups.",Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719544/),[h·ng] / [ml],1430,89610,DB00317,Gefitinib
,26898617,peak plasma concentration (Cmax),"The median peak plasma concentration (Cmax) was 377 (range, 168-781)ng/mL.",Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898617/),[ng] / [ml],377,96912,DB00317,Gefitinib
,26898617,area under the curve (AUC),"The median area under the curve (AUC) of the plasma concentration of gefitinib from 0 to 24h was 4893 (range, 698-13991) ng/mL h.",Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898617/),[ng] / [h·ml],4893,96913,DB00317,Gefitinib
,26898617,overall response rate,"The overall response rate was 82.9% (95% confidence interval, 66.4%-93.4%).",Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898617/),%,82.9,96914,DB00317,Gefitinib
,26898617,progression-free survival time,"The median progression-free survival time was 10 months, and the median survival time was 25 months.",Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898617/),month,10,96915,DB00317,Gefitinib
,20142724,objective response rate,"Thirteen patients treated at the MTD achieved a partial response (objective response rate: 37%; 95% confidence interval, 22-55) and 12 (34%) had stable disease.",Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20142724/),%,37,98967,DB00317,Gefitinib
,20142724,progression-free survival,"Median progression-free survival was 11 months (95% confidence interval, 6-17).",Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20142724/),month,11,98968,DB00317,Gefitinib
,32042822,Ctrough,The median of Ctrough was 175ng/mL (range from 47.8 to 470 ng/mL).,The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32042822/),[ng] / [ml],175,117944,DB00317,Gefitinib
,32042822,PFS,"ABCB1 rs10256836 recessive model was significantly correlated with PFS and patients with GG phenotype achieved longer PFS than patients with GC + CC phenotypes (17.40 vs. 10.33 months, P=0.040).",The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32042822/),month,17,117945,DB00317,Gefitinib
,32042822,PFS,"ABCB1 rs10256836 recessive model was significantly correlated with PFS and patients with GG phenotype achieved longer PFS than patients with GC + CC phenotypes (17.40 vs. 10.33 months, P=0.040).",The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32042822/),month,10.33,117946,DB00317,Gefitinib
,17216531,progression-free,"Median progression-free and overall survivals were 12.2 and 26.6 months, respectively.","Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216531/),month,12.2,119214,DB00317,Gefitinib
,17216531,overall survivals,"Median progression-free and overall survivals were 12.2 and 26.6 months, respectively.","Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216531/),month,26.6,119215,DB00317,Gefitinib
,16041611,AUC,"The geometric least square mean values for AUC were 3,407.6 versus 3,397.9 ng.h/ml in the absence and presence of tamoxifen, respectively (90% CL 0.894, 1.112) and for Cmax were 110.8 versus 103.6 ng/ml, respectively (90% CL 0.786, 1.111).",A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041611/),[h·ng] / [ml],"3,407.6",128074,DB00317,Gefitinib
,16041611,AUC,"The geometric least square mean values for AUC were 3,407.6 versus 3,397.9 ng.h/ml in the absence and presence of tamoxifen, respectively (90% CL 0.894, 1.112) and for Cmax were 110.8 versus 103.6 ng/ml, respectively (90% CL 0.786, 1.111).",A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041611/),[h·ng] / [ml],"3,397.9",128075,DB00317,Gefitinib
,16041611,Cmax,"The geometric least square mean values for AUC were 3,407.6 versus 3,397.9 ng.h/ml in the absence and presence of tamoxifen, respectively (90% CL 0.894, 1.112) and for Cmax were 110.8 versus 103.6 ng/ml, respectively (90% CL 0.786, 1.111).",A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041611/),[ng] / [ml],110.8,128076,DB00317,Gefitinib
,16041611,Cmax,"The geometric least square mean values for AUC were 3,407.6 versus 3,397.9 ng.h/ml in the absence and presence of tamoxifen, respectively (90% CL 0.894, 1.112) and for Cmax were 110.8 versus 103.6 ng/ml, respectively (90% CL 0.786, 1.111).",A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041611/),[ng] / [ml],103.6,128077,DB00317,Gefitinib
,28031710,particle,"The particle size, polydispersity index, and zeta potential of the optimized solution were 248.20 nm, 0.391, and -5.62 mV, respectively.","A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28031710/),nm,248.20,128750,DB00317,Gefitinib
,28031710,polydispersity index,"The particle size, polydispersity index, and zeta potential of the optimized solution were 248.20 nm, 0.391, and -5.62 mV, respectively.","A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28031710/),mv,0.391,128751,DB00317,Gefitinib
,28031710,zeta potential,"The particle size, polydispersity index, and zeta potential of the optimized solution were 248.20 nm, 0.391, and -5.62 mV, respectively.","A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28031710/),mv,-,128752,DB00317,Gefitinib
,28031710,zeta potential,"The particle size, polydispersity index, and zeta potential of the optimized solution were 248.20 nm, 0.391, and -5.62 mV, respectively.","A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28031710/),mv,5.62,128753,DB00317,Gefitinib
,28031710,half-life,"From the pharmacokinetic studies, half-life, Cmax, and Tmax of the drug of an optimized nanosuspension were found to be 8.65±1.99 h, 46,211.04±5,805.97 ng/mL, and 6.67±1.77 h, respectively.","A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28031710/),h,8.65,128754,DB00317,Gefitinib
,28031710,Cmax,"From the pharmacokinetic studies, half-life, Cmax, and Tmax of the drug of an optimized nanosuspension were found to be 8.65±1.99 h, 46,211.04±5,805.97 ng/mL, and 6.67±1.77 h, respectively.","A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28031710/),[ng] / [ml],"46,211.04",128755,DB00317,Gefitinib
,28031710,Tmax,"From the pharmacokinetic studies, half-life, Cmax, and Tmax of the drug of an optimized nanosuspension were found to be 8.65±1.99 h, 46,211.04±5,805.97 ng/mL, and 6.67±1.77 h, respectively.","A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28031710/),h,6.67,128756,DB00317,Gefitinib
,31867165,IC50,"WS-157 showed excellent inhibitory activities against EGFR (IC50 = 0.81 nmol/L), EGFR[d746-750] (IC50 = 1.2 nmol/L) and EGFR[L858R] (IC50 = 1.1 nmol/L), but was less effective or even inactive against other nine kinases.","Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31867165/),[nM] / [l],0.81,133214,DB00317,Gefitinib
,31867165,IC50,"WS-157 showed excellent inhibitory activities against EGFR (IC50 = 0.81 nmol/L), EGFR[d746-750] (IC50 = 1.2 nmol/L) and EGFR[L858R] (IC50 = 1.1 nmol/L), but was less effective or even inactive against other nine kinases.","Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31867165/),[nM] / [l],1.2,133215,DB00317,Gefitinib
,31867165,IC50,"WS-157 showed excellent inhibitory activities against EGFR (IC50 = 0.81 nmol/L), EGFR[d746-750] (IC50 = 1.2 nmol/L) and EGFR[L858R] (IC50 = 1.1 nmol/L), but was less effective or even inactive against other nine kinases.","Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31867165/),[nM] / [l],1.1,133216,DB00317,Gefitinib
,29346833,objective response rate (ORR),"Partial responses were achieved in 5 patients (4 confirmed), all in cohort 2; objective response rate (ORR) was 33% (duration, 1.9-6.4 months).","Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29346833/),%,33,138332,DB00317,Gefitinib
,17145877,brain ECF,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.21,139485,DB00317,Gefitinib
,17145877,brain ECF,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.61,139486,DB00317,Gefitinib
,17145877,to plasma AUC ratio,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.21,139487,DB00317,Gefitinib
,17145877,to plasma AUC ratio,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.61,139488,DB00317,Gefitinib
,17145877,CSF,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,1.18,139489,DB00317,Gefitinib
,17145877,to plasma AUC ratio,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,1.18,139490,DB00317,Gefitinib
,17145877,to plasma AUC ratio,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,1.30,139491,DB00317,Gefitinib
,17145877,brain ECF to plasma AUC ratio,"The brain ECF to plasma AUC ratio of unbound topotecan lactone increased by 1.6-fold to 0.35 +/- 0.04, which was significantly different from the ratio without gefitinib (P < 0.05).",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.35,139492,DB00317,Gefitinib
,17145877,CSF to plasma AUC ratio,The ventricular CSF to plasma AUC ratio significantly decreased to 0.98 +/- 0.05 (P < 0.05).,Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.98,139493,DB00317,Gefitinib
,22102379,flow-rate,The reconstituted solution was injected into an HPLC system and was subjected to reverse-phase HPLC on a 5 µm ODS-3 column at a flow-rate of 0.2 mL/min.,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),[ml] / [min],0.2,144009,DB00317,Gefitinib
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,817.4,144010,DB00317,Gefitinib
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,160.1,144011,DB00317,Gefitinib
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,142.3,144012,DB00317,Gefitinib
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,447.2,144013,DB00317,Gefitinib
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,128.3,144014,DB00317,Gefitinib
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,112.1,144015,DB00317,Gefitinib
more,22102379,extraction recovery,The extraction recovery of vinflunine was more than 80%.,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),%,80,144016,DB00317,Gefitinib
,16686369,bioavailability,"When administered orally, sulfasalazine is poorly absorbed with an estimated bioavailability of 3-12%.",Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16686369/),%,3-12,144972,DB00317,Gefitinib
,25891541,progression-free survival,The median progression-free survival (95% confidence interval) was 44.0 (22.0-133.0) days for the EGFR wild-type group (n=9) and 107.0 (74.0-224.0) days for the EGFR-activating mutation group (n=13).,Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25891541/),d,44.0,150388,DB00317,Gefitinib
,25891541,progression-free survival,The median progression-free survival (95% confidence interval) was 44.0 (22.0-133.0) days for the EGFR wild-type group (n=9) and 107.0 (74.0-224.0) days for the EGFR-activating mutation group (n=13).,Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25891541/),d,107.0,150389,DB00317,Gefitinib
,26559435,tissue to plasma partition coefficients (K pt),"Gefitinib demonstrated extensive distribution in most tissues, except for the brain, and tissue to plasma partition coefficients (K pt) ranged from 0.71 (brain) to 40.5 (liver).",A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26559435/),,0.71,152690,DB00317,Gefitinib
,26559435,tissue to plasma partition coefficients (K pt),"Gefitinib demonstrated extensive distribution in most tissues, except for the brain, and tissue to plasma partition coefficients (K pt) ranged from 0.71 (brain) to 40.5 (liver).",A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26559435/),,40.5,152691,DB00317,Gefitinib
,28176470,tmax,Median tmax was delayed from 5 to 6 hours.,Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28176470/),h,5,156993,DB00317,Gefitinib
,28176470,tmax,Median tmax was delayed from 5 to 6 hours.,Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28176470/),h,6,156994,DB00317,Gefitinib
,34354759,C max,"The results showed that a single intragastrically administered dose of Si Jun Zi Tang increased the pharmacokinetic parameters of gefitinib (C max, 3156.13 μg/L; A UC, 46281.5 μg/L/h) by 3 folds in rats compared with the administration of gefitinib alone (C max, 1352.07 μg/L; AUC, 11823.7 μg/L/h).",Effect of Single-Dose and Short-Term Administration of Si Jun Zi Tang on the Pharmacokinetics of Gefitinib in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34354759/),[μg] / [l],3156.13,158537,DB00317,Gefitinib
,34354759,A UC,"The results showed that a single intragastrically administered dose of Si Jun Zi Tang increased the pharmacokinetic parameters of gefitinib (C max, 3156.13 μg/L; A UC, 46281.5 μg/L/h) by 3 folds in rats compared with the administration of gefitinib alone (C max, 1352.07 μg/L; AUC, 11823.7 μg/L/h).",Effect of Single-Dose and Short-Term Administration of Si Jun Zi Tang on the Pharmacokinetics of Gefitinib in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34354759/),[μg] / [h·l],46281.5,158538,DB00317,Gefitinib
,34354759,C max,"The results showed that a single intragastrically administered dose of Si Jun Zi Tang increased the pharmacokinetic parameters of gefitinib (C max, 3156.13 μg/L; A UC, 46281.5 μg/L/h) by 3 folds in rats compared with the administration of gefitinib alone (C max, 1352.07 μg/L; AUC, 11823.7 μg/L/h).",Effect of Single-Dose and Short-Term Administration of Si Jun Zi Tang on the Pharmacokinetics of Gefitinib in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34354759/),[μg] / [l],1352.07,158539,DB00317,Gefitinib
,34354759,AUC,"The results showed that a single intragastrically administered dose of Si Jun Zi Tang increased the pharmacokinetic parameters of gefitinib (C max, 3156.13 μg/L; A UC, 46281.5 μg/L/h) by 3 folds in rats compared with the administration of gefitinib alone (C max, 1352.07 μg/L; AUC, 11823.7 μg/L/h).",Effect of Single-Dose and Short-Term Administration of Si Jun Zi Tang on the Pharmacokinetics of Gefitinib in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34354759/),[μg] / [h·l],11823.7,158540,DB00317,Gefitinib
,21681573,concentrations,"The plasma and CSF concentrations of erlotinib at a dose of 75 mg were 433 and 14 nM, respectively.",Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21681573/),,14,163535,DB00317,Gefitinib
,21681573,CSF,"The mean ± standard deviation of CSF concentrations and penetration rates were 106 ± 59 nM and 4.5 ± 1.5%, respectively.",Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21681573/),nM,106,163536,DB00317,Gefitinib
,21681573,concentrations,"The mean ± standard deviation of CSF concentrations and penetration rates were 106 ± 59 nM and 4.5 ± 1.5%, respectively.",Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21681573/),nM,106,163537,DB00317,Gefitinib
,21681573,penetration rates,"The mean ± standard deviation of CSF concentrations and penetration rates were 106 ± 59 nM and 4.5 ± 1.5%, respectively.",Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21681573/),%,4.5,163538,DB00317,Gefitinib
,29193123,AUC(0-24) ratios,"Predicted and observed metoprolol geometric least-squares mean AUC(0-24) ratios in UM vs EM were also similar (0.46 and 0.55, respectively), suggesting that system components related to CYP2D6 in the PBPK model were properly established.",Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29193123/),,0.46,180852,DB00317,Gefitinib
,29193123,AUC(0-24) ratios,"Predicted and observed metoprolol geometric least-squares mean AUC(0-24) ratios in UM vs EM were also similar (0.46 and 0.55, respectively), suggesting that system components related to CYP2D6 in the PBPK model were properly established.",Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29193123/),,0.55,180853,DB00317,Gefitinib
,25072946,constant flow rate,"After liquid-liquid extraction with diethyl ether, pazopanib and gefitinib (internal standard) were separated using isocratic elution on an Ultrabase C18 column using a mobile phase consisting of a mixture in vol/vol proportion of 47:53 of ammonium acetate (pH, 7; 0.02 mol/L) and acetonitrile/methanol (70:30, vol/vol) pumped at a constant flow rate of 1 mL/min.",Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072946/),[ml] / [min],1,189825,DB00317,Gefitinib
>,25072946,Recovery,Recovery of pazopanib from plasma was >80%.,Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072946/),%,80,189826,DB00317,Gefitinib
,32508029,area under plasma concentration-time curve for the steady state,The area under plasma concentration-time curve for the steady state of apatinib was 2864.73 ± 2605.54 ng mL-1 h-1 in Cohort A and 2445.09 ± 1550.89 ng mL-1 h-1 in Cohort B.,Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32508029/),[ng] / [h·ml],2864.73,190563,DB00317,Gefitinib
,32508029,area under plasma concentration-time curve for the steady state,The area under plasma concentration-time curve for the steady state of apatinib was 2864.73 ± 2605.54 ng mL-1 h-1 in Cohort A and 2445.09 ± 1550.89 ng mL-1 h-1 in Cohort B.,Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32508029/),[ng] / [h·ml],2445.09,190564,DB00317,Gefitinib
,32508029,PFS,"Patients without a concomitant mutation at baseline had a prolonged PFS tendency (20.99 months v 13.21 months, P = .0624).",Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32508029/),month,20.99,190565,DB00317,Gefitinib
,32508029,PFS,"Patients without a concomitant mutation at baseline had a prolonged PFS tendency (20.99 months v 13.21 months, P = .0624).",Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32508029/),month,13.21,190566,DB00317,Gefitinib
,25848356,trough level,We speculated that the plasma concentration of gefitinib reached the steady state at least by day 16 after the start of gefitinib (626.6 ng/ml at trough level).,Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25848356/),[ng] / [ml],626.6,193112,DB00317,Gefitinib
,25848356,trough level,"On day 46, the plasma concentration was 538.4 ng/ml at trough level and the concentration in the peritoneal dialysis fluid was 34.6 ng/ml, suggesting that CAPD appeared to have little effect on the pharmacokinetics of gefitinib.",Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25848356/),ng,538.4,193113,DB00317,Gefitinib
,33280466,peak plasma concentrations,"Rapid oral absorption resulted in peak plasma concentrations at 1 h of ca. 7 µg/mL, that declined with a half-life of 3.8 h (2.6 h for the IV route), and providing an estimated oral bioavailability of 53%.","Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280466/),[μg] / [ml],7,202724,DB00317,Gefitinib
,33280466,half-life,"Rapid oral absorption resulted in peak plasma concentrations at 1 h of ca. 7 µg/mL, that declined with a half-life of 3.8 h (2.6 h for the IV route), and providing an estimated oral bioavailability of 53%.","Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280466/),h,3.8,202725,DB00317,Gefitinib
,33280466,half-life,"Rapid oral absorption resulted in peak plasma concentrations at 1 h of ca. 7 µg/mL, that declined with a half-life of 3.8 h (2.6 h for the IV route), and providing an estimated oral bioavailability of 53%.","Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280466/),h,2.6,202726,DB00317,Gefitinib
,33280466,oral bioavailability,"Rapid oral absorption resulted in peak plasma concentrations at 1 h of ca. 7 µg/mL, that declined with a half-life of 3.8 h (2.6 h for the IV route), and providing an estimated oral bioavailability of 53%.","Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280466/),%,53,202727,DB00317,Gefitinib
,28391354,survival,"For the patients with exon 19 deletions, there was no significant difference in PFS between the high and low plasma concentration groups (median survival: 12.0 vs. 17.0 months, P = 0.9548).",Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28391354/),,12,204189,DB00317,Gefitinib
,26795401,run time,"The chromatography run time was 6min using an Agilent RRHD SB-C18 column with a gradient of acetonitrile and water (0.1% formic acid, v/v).",Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795401/),min,6,209491,DB00317,Gefitinib
,26795401,extraction recoveries,The extraction recoveries were in the range of 86-105% and no significant matrix effect was observed.,Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795401/),%,86-105,209492,DB00317,Gefitinib
,30131694,maximum plasma concentration (Tmax),"The median maximum plasma concentration (Tmax) was 4-5 h, and the mean elimination half-life (t1/2) was 18-26 h.",Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30131694/),h,4-5,211307,DB00317,Gefitinib
,30131694,elimination half-life (t1/2),"The median maximum plasma concentration (Tmax) was 4-5 h, and the mean elimination half-life (t1/2) was 18-26 h.",Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30131694/),h,18-26,211308,DB00317,Gefitinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.41,212573,DB00317,Gefitinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.39,212574,DB00317,Gefitinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.57,212575,DB00317,Gefitinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.24,212576,DB00317,Gefitinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.21,212577,DB00317,Gefitinib
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.31,212578,DB00317,Gefitinib
,17575239,Cl(max),"CYP2D6 was involved in gefitinib metabolism (Cl(max), 0.63 mL/min/nmol) to a large extent, whereas CYP1A2 was considerably involved in erlotinib metabolism (Cl(max), 0.15 mL/min/nmol).",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.63,212579,DB00317,Gefitinib
,17575239,Cl(max),"CYP2D6 was involved in gefitinib metabolism (Cl(max), 0.63 mL/min/nmol) to a large extent, whereas CYP1A2 was considerably involved in erlotinib metabolism (Cl(max), 0.15 mL/min/nmol).",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.15,212580,DB00317,Gefitinib
,15598479,AUC,"The geometric mean AUC was 2219 ng.h/mL for a single 250-mg dose of gefitinib administered as a whole tablet, 2233 ng.h/mL for the dispersion preparation administered by drink, and 2007 ng.h/mL for the dispersion preparation administered by nasogastric tube.","Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598479/),[h·ng] / [ml],2219,217556,DB00317,Gefitinib
,15598479,AUC,"The geometric mean AUC was 2219 ng.h/mL for a single 250-mg dose of gefitinib administered as a whole tablet, 2233 ng.h/mL for the dispersion preparation administered by drink, and 2007 ng.h/mL for the dispersion preparation administered by nasogastric tube.","Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598479/),[h·ng] / [ml],2233,217557,DB00317,Gefitinib
,15598479,AUC,"The geometric mean AUC was 2219 ng.h/mL for a single 250-mg dose of gefitinib administered as a whole tablet, 2233 ng.h/mL for the dispersion preparation administered by drink, and 2007 ng.h/mL for the dispersion preparation administered by nasogastric tube.","Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598479/),[h·ng] / [ml],2007,217558,DB00317,Gefitinib
,15598479,C(max),"The corresponding values for the geometric mean C(max) were 95.2, 96.3, and 89.9 ng/mL.","Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598479/),[ng] / [ml],95.2,217559,DB00317,Gefitinib
,15598479,C(max),"The corresponding values for the geometric mean C(max) were 95.2, 96.3, and 89.9 ng/mL.","Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598479/),[ng] / [ml],96.3,217560,DB00317,Gefitinib
,15598479,C(max),"The corresponding values for the geometric mean C(max) were 95.2, 96.3, and 89.9 ng/mL.","Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598479/),[ng] / [ml],89.9,217561,DB00317,Gefitinib
,15598479,bioavailability,The gefitinib dispersion preparation administered by drink had a mean bioavailability of 103.8% relative to the whole tablet; the dispersion preparation administered by nasogastric tube had a mean bioavailability of 99.1% relative to the whole tablet.,"Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598479/),%,103.8,217562,DB00317,Gefitinib
,15598479,bioavailability,The gefitinib dispersion preparation administered by drink had a mean bioavailability of 103.8% relative to the whole tablet; the dispersion preparation administered by nasogastric tube had a mean bioavailability of 99.1% relative to the whole tablet.,"Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15598479/),%,99.1,217563,DB00317,Gefitinib
,25788260,CSF-to-plasma ratio,"The CSF-to-plasma ratio of gefitinib in patients with BM was higher than that in patients without BM (1.34% vs. 0.36%, P < 0.001).",Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25788260/),%,1.34,218649,DB00317,Gefitinib
,25788260,CSF-to-plasma ratio,"The CSF-to-plasma ratio of gefitinib in patients with BM was higher than that in patients without BM (1.34% vs. 0.36%, P < 0.001).",Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25788260/),%,0.36,218650,DB00317,Gefitinib
,25788260,time to progression of brain lesions,"The median time to progression of brain lesions and the median overall survival were 7.07 and 15.4 months, respectively.",Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25788260/),month,7.07,218651,DB00317,Gefitinib
,25788260,overall survival,"The median time to progression of brain lesions and the median overall survival were 7.07 and 15.4 months, respectively.",Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25788260/),month,15.4,218652,DB00317,Gefitinib
,19396601,peak serum calcitriol concentration (C (max)),Mean (+/-SE) peak serum calcitriol concentration (C (max)) at the MTD (125 microg/week calcitriol) was 11.17 +/- 2.62 ng/ml and the systemic exposure (AUC(0-72 h)) of 53.30 +/- 10.49 ng h/ml.,A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19396601/),[ng] / [ml],11.17,222257,DB00317,Gefitinib
,19396601,AUC(0-72 h)),Mean (+/-SE) peak serum calcitriol concentration (C (max)) at the MTD (125 microg/week calcitriol) was 11.17 +/- 2.62 ng/ml and the systemic exposure (AUC(0-72 h)) of 53.30 +/- 10.49 ng h/ml.,A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19396601/),[h·ng] / [ml],53.30,222258,DB00317,Gefitinib
,11368294,terminal elimination half-life (t1/2beta),The terminal elimination half-life (t1/2beta) was 28 hours (range 12 to 51 hours).,Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368294/),h,28,223475,DB00317,Gefitinib
<,11368294,Urinary recovery,"Urinary recovery of ZD1839 was <0.5%, indicating that this was not a major route of elimination.",Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368294/),%,0.5,223476,DB00317,Gefitinib
,19687340,MTD,The MTD of the combination regimen was 15 mg/m(2)/d of IV irinotecan for 5 days of 2 consecutive weeks and 112.5 mg/m(2)/d of gefitinib given for 12 days.,Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19687340/),[mg] / [d·m(2)],15,225785,DB00317,Gefitinib
,19687340,MTD,The MTD of the combination regimen was 15 mg/m(2)/d of IV irinotecan for 5 days of 2 consecutive weeks and 112.5 mg/m(2)/d of gefitinib given for 12 days.,Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19687340/),[mg] / [d·m(2)],112.5,225786,DB00317,Gefitinib
,19687340,bioavailability,"Gefitinib increased the bioavailability of oral irinotecan by four-fold over that observed in historical controls (median, 0.09 v 0.42; P < .000001), reducing the apparent clearance (an inverse measure of exposure) of irinotecan and SN-38 by 37% and 38%, respectively (P < .0001).",Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19687340/),,0.09,225787,DB00317,Gefitinib
,19687340,bioavailability,"Gefitinib increased the bioavailability of oral irinotecan by four-fold over that observed in historical controls (median, 0.09 v 0.42; P < .000001), reducing the apparent clearance (an inverse measure of exposure) of irinotecan and SN-38 by 37% and 38%, respectively (P < .0001).",Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19687340/),,0.42,225788,DB00317,Gefitinib
,16231967,Oral bioavailability,Study 1: Oral bioavailability of a gefitinib 250 mg dose was 57% in healthy volunteers.,Single-dose clinical pharmacokinetic studies of gefitinib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231967/),%,57,229113,DB00317,Gefitinib
,16231967,peak plasma concentration (Cmax),"Absorption was moderately slow, with geometric mean (gmean) peak plasma concentration (Cmax) of 85 ng/mL (range 43.5-110 ng/mL) reached 5 hours following an oral dose of 250 mg.",Single-dose clinical pharmacokinetic studies of gefitinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231967/),[ng] / [ml],85,229114,DB00317,Gefitinib
,16231967,Oral bioavailability,Study 2: Oral bioavailability of a gefitinib 250 mg dose was 59% in patients.,Single-dose clinical pharmacokinetic studies of gefitinib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231967/),%,59,229115,DB00317,Gefitinib
,16231967,Cmax,"Absorption was again moderately slow, with gmean Cmax of 159 ng/mL (range 48.7-324 ng/mL) typically reached 3 hours (range 1-8 hours) following an oral dose of 250 mg.",Single-dose clinical pharmacokinetic studies of gefitinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231967/),[ng] / [ml],159,229116,DB00317,Gefitinib
,20651613,ratio,"The median plasma gefitinib values were 662 ng/ml on D3 and 1064 ng/ml on D8, and the D8/D3 ratio was 1.587.",Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20651613/),,1.587,229414,DB00317,Gefitinib
,20651613,progression-free survival (PFS),"The median progression-free survival (PFS) was 71 days, and the median overall survival was 224 days.",Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20651613/),d,71,229415,DB00317,Gefitinib
,20651613,overall survival,"The median progression-free survival (PFS) was 71 days, and the median overall survival was 224 days.",Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20651613/),d,224,229416,DB00317,Gefitinib
over,30326566,net efflux ratio,"According to U.S. Food and Drug Administration (FDA) criteria, FFC was found to be a potential BCRP substrate due to the net efflux ratio being over 2.0 (2.37) in MDCK cells stably transfected with chicken BCRP and the efflux completely reversed by a BCRP inhibitor (Gefitinib).",Relevance of Breast Cancer Resistance Protein to Pharmacokinetics of Florfenicol in Chickens: A Perspective from In Vivo and In Vitro Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326566/),,2.0,234319,DB00317,Gefitinib
,16502356,fu,"It was found that gefitinib was extensively bound in human rat mouse and dog plasma with mean fu values of 3.4%, 3.8%, 5.1% and 6.0% respectively.","Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502356/),%,3.4,237598,DB00317,Gefitinib
,16502356,fu,"It was found that gefitinib was extensively bound in human rat mouse and dog plasma with mean fu values of 3.4%, 3.8%, 5.1% and 6.0% respectively.","Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502356/),%,3.8,237599,DB00317,Gefitinib
,16502356,fu,"It was found that gefitinib was extensively bound in human rat mouse and dog plasma with mean fu values of 3.4%, 3.8%, 5.1% and 6.0% respectively.","Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502356/),%,5.1,237600,DB00317,Gefitinib
,16502356,fu,"It was found that gefitinib was extensively bound in human rat mouse and dog plasma with mean fu values of 3.4%, 3.8%, 5.1% and 6.0% respectively.","Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502356/),%,6.0,237601,DB00317,Gefitinib
,16502356,binding constants,In isolated protein solutions approximately 90% and 78% of gefitinib was bound to human serum albumin (HSA) (40 mg/dL) and alpha1-acid glycoprotein (AAG) (1.4 mg/dL) with binding constants of 1.85 x 10(4) M(-1) and 1.13 x 10(5) M(-1) respectively.,"Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502356/),1/[M],1.85 x 10(4),237602,DB00317,Gefitinib
,16502356,binding constants,In isolated protein solutions approximately 90% and 78% of gefitinib was bound to human serum albumin (HSA) (40 mg/dL) and alpha1-acid glycoprotein (AAG) (1.4 mg/dL) with binding constants of 1.85 x 10(4) M(-1) and 1.13 x 10(5) M(-1) respectively.,"Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502356/),1/[M],1.13 x 10(5),237603,DB00317,Gefitinib
,16502356,fu,In plasma from cancer patients fu at pre-treatment varied 2.4-fold (mean 3.4 +/- 0.6%; range 2.2-5.4%) and fu was constant over the 28-days of treatment (P > 0.05).,"Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502356/),%,3.4,237604,DB00317,Gefitinib
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),nm,331,238331,DB00317,Gefitinib
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],3400,238332,DB00317,Gefitinib
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],2956,238333,DB00317,Gefitinib
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],1625,238334,DB00317,Gefitinib
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],1500,238335,DB00317,Gefitinib
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],1110,238336,DB00317,Gefitinib
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],1028,238337,DB00317,Gefitinib
,24794908,bioavailability,"Pharmacokinetically, after oral administration, gefitinib is slowly absorbed with bioavailability of approximately 60% in human.",Gefitinib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),%,60,238338,DB00317,Gefitinib
,24794908,total plasma clearance,Gefitinib is eliminated mainly hepatically with total plasma clearance of 595mL/min after intravenous administration.,Gefitinib. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),[ml] / [min],595,238339,DB00317,Gefitinib
,31261446,Recoveries,Recoveries (87.74-99.96%) and matrix effects (86.60-106.40%) were satisfactory in the biological matrix examined.,A validated high-performance liquid chromatography-tandem mass spectrometry method for quantification of gefitinib and its main metabolites in xenograft mouse tumor: Application to a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31261446/),%,87.74-99.96,240770,DB00317,Gefitinib
,21703945,flow rate,The flow rate was 300 μL/min.,"Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21703945/),[μl] / [min],300,246444,DB00317,Gefitinib
,21703945,ch,The chromatographic run time was 3 min.,"Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21703945/),min,3,246445,DB00317,Gefitinib
,21703945,run time,The chromatographic run time was 3 min.,"Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21703945/),min,3,246446,DB00317,Gefitinib
,21220471,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 45 mg/d.,"Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220471/),[mg] / [d],45,247433,DB00317,Gefitinib
,21220471,MTD,The MTD of PF299804 is 45 mg/d.,"Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220471/),[mg] / [d],45,247434,DB00317,Gefitinib
,25521398,overall survival,"Median PFS was 15.4 weeks (95% CI, 9.7-17.6); median overall survival was 46.3 weeks (95% CI, 32.7-not reached); and the objective response rate was 17.1% (95% CI, 7.2-32.1).",Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25521398/),weeks,46.3,249892,DB00317,Gefitinib
,25521398,objective response rate,"Median PFS was 15.4 weeks (95% CI, 9.7-17.6); median overall survival was 46.3 weeks (95% CI, 32.7-not reached); and the objective response rate was 17.1% (95% CI, 7.2-32.1).",Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25521398/),%,17.1,249893,DB00317,Gefitinib
,33098714,Ki,Gefitinib was demonstrated to be a strong inhibitor of CYP1A1 with Ki value of 0.095 μM.,Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33098714/),μM,0.095,251802,DB00317,Gefitinib
,16135484,peak gefitinib plasma concentration,"At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration.",Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16135484/),[μg] / [ml],2.2,260166,DB00317,Gefitinib
,16135484,apparent clearance,"The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively.",Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16135484/),[l] / [h·m2],14.8,260167,DB00317,Gefitinib
,16135484,half-life,"The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively.",Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16135484/),h,11.7,260168,DB00317,Gefitinib
,27339148,trough levels,The median trough levels were: 197 ng/ml 10 h from the first administration of gefitinib; 113 ng/ml on D2; and 358 ng/ml on D8.,Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27339148/),[ng] / [ml],197,260484,DB00317,Gefitinib
,27339148,trough levels,The median trough levels were: 197 ng/ml 10 h from the first administration of gefitinib; 113 ng/ml on D2; and 358 ng/ml on D8.,Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27339148/),[ng] / [ml],113,260485,DB00317,Gefitinib
,27339148,trough levels,The median trough levels were: 197 ng/ml 10 h from the first administration of gefitinib; 113 ng/ml on D2; and 358 ng/ml on D8.,Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27339148/),[ng] / [ml],358,260486,DB00317,Gefitinib
,27339148,D8/D2 ratio,"The median D8/D2 ratio was 2.709, and the median elimination half-life was 15.7 h.",Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27339148/),,2.709,260487,DB00317,Gefitinib
,27339148,elimination half-life,"The median D8/D2 ratio was 2.709, and the median elimination half-life was 15.7 h.",Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27339148/),h,15.7,260488,DB00317,Gefitinib
,27339148,progression-free survival (PFS),"The median progression-free survival (PFS) was 273 days, and the median overall survival (OS) was 933 days.",Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27339148/),d,273,260489,DB00317,Gefitinib
,27339148,overall survival (OS),"The median progression-free survival (PFS) was 273 days, and the median overall survival (OS) was 933 days.",Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27339148/),d,933,260490,DB00317,Gefitinib
,17694310,maximum dose,The starting dose of temozolomide was 150 mg/m(2)/day for 5 days every 28 days and could be escalated to a maximum dose of 200 mg/m(2)/day in subsequent cycles.,Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694310/),[mg] / [m],200,260762,DB00317,Gefitinib
,17694310,MTD,"For patients on EIAEDs, the MTD of gefitinib was 1,000 mg/day in combination with temozolomide.",Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694310/),[mg] / [d],"1,000",260763,DB00317,Gefitinib
,17694310,MTD,"For patients not on EIAEDs, the MTD was 250 mg/day in combination with temozolomide.",Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694310/),[mg] / [d],250,260764,DB00317,Gefitinib
,17694310,terminal half-life,"The peak concentration and AUC(0-24hr) at the 500 mg dose level was 1.8 and 2.5-fold lower, respectively, in the EIAED group compared to the non-EIAED group; trough levels of gefitinib increased in both groups consistent with the reported terminal half-life ranging from 27 to 51 h.",Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694310/),h,27 to 51,260765,DB00317,Gefitinib
,11980995,terminal half-life,"Exposure to ZD1839 was dose proportional, and the mean terminal half-life was 48 hours (range, 37 to 65).","ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11980995/),h,48,261257,DB00317,Gefitinib
>,21796439,response rate,A response rate >55% was sought.,A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796439/),%,55,262719,DB00317,Gefitinib
,21796439,exposure (,"Median (range) systemic irinotecan exposure (AUC) was 283 ng/ml*hr (range, 163-890 ng/ml*hr) and 28 ng/ml*hr (3.6-297 ng/ml*hr) for the active metabolite, SN-38.",A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796439/),[ng] / [h·ml],283,262720,DB00317,Gefitinib
,21796439,AUC),"Median (range) systemic irinotecan exposure (AUC) was 283 ng/ml*hr (range, 163-890 ng/ml*hr) and 28 ng/ml*hr (3.6-297 ng/ml*hr) for the active metabolite, SN-38.",A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796439/),[ng] / [h·ml],283,262721,DB00317,Gefitinib
,21796439,AUC),"Median (range) systemic irinotecan exposure (AUC) was 283 ng/ml*hr (range, 163-890 ng/ml*hr) and 28 ng/ml*hr (3.6-297 ng/ml*hr) for the active metabolite, SN-38.",A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796439/),[ng] / [h·ml],28,262722,DB00317,Gefitinib
,16467100,MTD,"The MTD was 500 mg of gefitinib plus 5 mg of sirolimus for patients not on EIAEDs and 1,000 mg of gefitinib plus 10 mg of sirolimus for patients on EIAEDs.",Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16467100/),mg,500,265969,DB00317,Gefitinib
,16467100,MTD,"The MTD was 500 mg of gefitinib plus 5 mg of sirolimus for patients not on EIAEDs and 1,000 mg of gefitinib plus 10 mg of sirolimus for patients on EIAEDs.",Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16467100/),mg,1,265970,DB00317,Gefitinib
,17237473,objective tumour response rate,"For the patients treated at RDL, the objective tumour response rate was 11.1% (95% confidence interval 2.4% to 29.2%) and median survival was 9.3 months.","Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17237473/),%,11.1,268674,DB00317,Gefitinib
,16568471,time to progression,"A partial objective tumor response was demonstrated in 1 of 13 evaluable patients (7.7%) in each dose group; the median time to progression for both doses combined was 185 days (range, 28-233 days).",Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16568471/),d,185,272289,DB00317,Gefitinib
,26966895,flow rate,"Chromatographic separation was performed on a Waters BEH C18 column with an isocratic elution using a mobile phase composed of acetonitrile and water, each with 0.1% formic acid, (80: 20, v/v), at a flow rate of 0.2 mL/min.",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),[ml] / [min],0.2,273626,DB00317,Gefitinib
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,36,273627,DB00317,Gefitinib
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,147.02,273628,DB00317,Gefitinib
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,170.16,273629,DB00317,Gefitinib
,26966895,Er%,The method provided good extraction recovery of all analytes from rat plasma (Er% from -14.05 to -1.08).,Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,1,273630,DB00317,Gefitinib
